Oral Amylin and the Next Frontier in Obesity Medicine: What Structure Therapeutics Just Showed

The obesity drug pipeline has been dominated by a single question for three years: which injectable GLP-1 or combination works best?

That question isn't going away. But a new one is emerging alongside it: what does obesity medicine look like when nothing requires a needle?

On September 8, 2026, Structure Therapeutics reported two significant data readouts that push that question further than it's ever been tested in humans.

---

What Structure Therapeutics Reported

ACCG-2671: First human data for an oral small-molecule amylin agonist

Structure Therapeutics reported Phase 1/2a results for ACCG-2671 — a once-weekly oral dual amylin/calcitonin receptor agonist. This is the first oral small-molecule amylin program to report human data.

Trial design: Phase 1/2a single-ascending-dose (SAD) study — 31 healthy adult participants without obesity, single doses of 1, 2, 5 or 10 mg of ACCG-2671 or placebo.

Key findings:

• Terminal half-life approximately 6 days, Tmax 1–1.5 hours — consistent with once-weekly oral dosing
• A single 10 mg dose (n=6) was associated with mean body-weight reduction of 3.3% at Day 24
• No serious adverse events; no drug-related adverse events leading to discontinuation
• No nausea or vomiting at placebo, 1 mg or 2 mg; at 5 mg, nausea in 4 of 5 and vomiting in 3 of 5 participants; at 10 mg, gastrointestinal events in 6 of 6

The randomized, placebo-controlled multiple-ascending-dose portion will dose ACCG-2671 for 84 days across five cohorts of participants living with obesity, with daily and weekly regimens and one cohort on a stable dose of an injectable GLP-1 receptor agonist. Topline data are expected in the first half of 2027.

Source: Structure Therapeutics SEC filing, September 8, 2026. sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm

What this data does and doesn't show: This is a Phase 1 study in 31 healthy adults — not obese patients, not a controlled efficacy trial. The -3.3% weight loss figure comes from 6 people at the highest dose. These numbers are hypothesis-generating, not proof of efficacy at scale. The nausea signal at higher doses is a real development challenge for any oral amylin program.

What it does show: the molecule gets into humans with the pharmacokinetics needed for weekly oral dosing, and it produces biological signals consistent with amylin receptor engagement. That's the minimum bar for advancing to larger trials.

---

Aleniglipron: 72-Week Oral GLP-1 Data

Structure also reported 72-week data from the ACCESS OLE — a prespecified 36-week open-label extension of the Phase 2b ACCESS trial (NCT06693843) — for aleniglipron, its once-daily oral non-peptide GLP-1 receptor agonist.

Key findings:

• Participants continuing through the extension lost 11.6% (45 mg), 14.4% (90 mg) and 16.2% (120 mg) of body weight; the placebo group that crossed over lost 9.0%
• More than one-third of participants in the two highest-dose cohorts lost over 20%
• Fewer than 5% discontinued due to adverse events
• Participants who started at 2.5 mg with gradual titration had better GI tolerability than those who started at 5 mg
• Structure reports no evidence of a weight-loss plateau in the two top doses at week 72

Source: Structure Therapeutics SEC filing, September 8, 2026.

Important context: This is an open-label extension — not a new placebo-controlled efficacy trial. Participants who continued to 72 weeks were likely those who tolerated the drug and were experiencing benefit. That selection effect means the weight loss figures should not be directly compared to primary efficacy endpoints from controlled trials.

That said, 16.2% weight loss at 72 weeks in an open-label extension of an oral drug — with fewer than 5% discontinuing for adverse events — is a meaningful clinical signal.

Results from a 44-week Phase 2 body-composition trial of aleniglipron (NCT07169942) are expected in the fourth quarter of 2026. That's exactly where GLP-1 2.0 research needs to go: not just how much weight, but what kind of weight.

---

Why the Amylin Mechanism Matters Differently Here

Every amylin agonist with late-stage data is a peptide:

• Cagrilintide (Novo Nordisk): Injectable, in CagriSema Phase 3
• Eloralintide (Eli Lilly): Injectable, Phase 3 underway
• Zenagamtide (Novo Nordisk, formerly amycretin): GLP-1/amylin co-agonist, Phase 3, in both subcutaneous and oral peptide formulations

The amylin receptor is a validated obesity target. CagriSema showed 22.7% weight loss at 68 weeks in Phase 3. Eloralintide showed −20% at 48 weeks at the 9 mg dose in Phase 2, against −0.4% on placebo. The mechanism works.

The question has always been chemistry. Amylin analogs are peptides — even in an oral formulation they face the bioavailability limits of GLP-1 peptides. ACCG-2671 is not a peptide. It's a small molecule designed to activate the amylin receptor — an entirely different chemical approach to the same biological target.

If a small-molecule amylin agonist can produce meaningful obesity outcomes with acceptable tolerability, it opens a development pathway that:

• Doesn't require injection
• Can potentially be manufactured at lower cost than peptides
• Can be combined with oral GLP-1 agonists in a fully oral combination regimen

---

The Oral Obesity Pipeline — Where It Stands

The pipeline has moved faster than most people realize:

Approved oral options:

• Orforglipron (Foundayo, Eli Lilly): FDA approved April 1, 2026 — non-peptide GLP-1, no food, water or time-of-day restrictions. ATTAIN-1: −12.4% (27.3 lb) at 72 weeks at the highest dose vs −0.9% on placebo.
• Wegovy pill (oral semaglutide 25 mg, Novo Nordisk): FDA approved December 22, 2025; US launch January 2026. OASIS 4: 16.6% mean weight loss at 64 weeks when treatment was adhered to; one in three lost 20% or more.

Advanced development:

• Aleniglipron (Structure Therapeutics): 72-week ACCESS OLE data reported September 8, 2026 — −16.2% at the highest dose. Body-composition results expected Q4 2026.

Early stage:

• ACCG-2671 (Structure Therapeutics): Phase 1/2a, first human data September 8, 2026. Oral amylin.

The direction is clear: injectable therapy remains the efficacy gold standard today, but the oral pipeline is catching up faster than most forecasts anticipated. And the amylin oral approach, if it works, adds a second mechanism to the oral toolkit.

---

What This Means for the GLP-1 2.0 Framework

The oral pipeline accelerates the access problem. When obesity therapy doesn't require a weekly injection, the patient population willing and able to use it expands dramatically. More patients, faster uptake, broader demographics — and more people navigating these protocols without adequate tracking infrastructure.

This is exactly where the GLP-1 2.0 tracking layer matters.

The drug changes. The need to measure body composition, track protocol changes, monitor biomarkers, and connect daily symptoms to outcomes — that need grows as access expands, not shrinks.

Results from the 44-week aleniglipron body-composition trial are expected in the fourth quarter of 2026. That's the right question to be asking. We'll cover it when the data arrives.

→ Track your protocol at PeptidesGPT.com/research

---

Sources:

• Structure Therapeutics. "Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management." Exhibit 99.1, Form 8-K, September 8, 2026. sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm
• Billings LK, et al. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." Lancet. 2025;406(10520):2631–2643. PMID 41207310. DOI 10.1016/S0140-6736(25)02155-5.
• CagriSema REDEFINE 1: Novo Nordisk, ADA 2026 (figure carried from the site's earlier coverage).
• Eli Lilly. "FDA approves Lilly's Foundayo (orforglipron)…" Investor release, April 1, 2026.
• Novo Nordisk. "Wegovy pill FDA approval." Company announcement, December 22, 2025.

---

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider.